The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
…Fernandez-Cuesta and colleagues showed supra-carcinoids had a high expression of immune checkpoint genes. These experiments will further explore the potential of immunotherapy. What is the next step? The laboratory models…
…T-cell therapy, immunotherapy, PRRT, and most recently, smart chemotherapy and a cancer vaccine. “Carol cared deeply about NETRF, but even more deeply about our staff, fellow Board members, and supporters,”…
…personalized treatment plan for every patient, which may include systemic therapies, such as targeted therapy, immunotherapy, or chemotherapy, either as standard-of-care or as part of a clinical trial. Systemic therapy…
…cancer (oncology), blood (hematology), radiology, pathology, gastroenterology, endocrinology, and nutrition. Mount Sinai is working to find the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches…
…meeting, and some of the most exciting, included advances in immunotherapy as well as ways to improve on current therapies, such as PRRT, and ways to broaden treatment strategies to…
General Description We propose to characterize the response of neuroendocrine tumors to PD-1 inhibition in an ex vivo tissue slice culture model. Using this model, we will assess changes in…
General Description Pancreatic neuroendocrine tumors (NETs), are rare morphologically well-differentiated malignancies with an unacceptably poor 5-year survival rate of 20%. Multiple lines of evidence suggest that immunosuppressive Tregs play a…
…renowned for his work in immunotherapy. In particular, Dr. June’s team spent many years developing CAR T-cell “serial killer”, which have been successful in treating patients with forms of leukemia…
…on the potential for neuroendocrine tumors to respond to currently available immune checkpoint inhibitors, and inform future strategies for immunotherapy in neuroendocrine tumors. Publications da Silva A, Bowden M, Zhang…
…one round of aggressive chemo as the slow-growing cancer became fast growing. When that didn’t stop the growth, she completed one round of immunotherapy. Meg was racing the clock needing…
